MAPS responds to report that Resilient has resubmitted its MDMA therapy NDA to FDA
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
MAPS said it welcomed a new FDAFDAThe Food and Drug Administration, the United States regulator of medicines, medical devices and food.Open the glossary evaluation after an August 9 report by Psychedelic Alpha that Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) had resubmitted its new drug applicationNDAA new drug application, the formal request asking the FDA to approve a new medicine for sale in the United States.Open the glossary for MDMA-assisted therapy for PTSDPTSDPost-traumatic stress disorder, a mental health condition that can follow exposure to a traumatic event.Open the glossary. The resubmission follows the Complete Response Letter issued on August 9, 2024, which recommended additional research on durability of response, safety characterisation and steps to minimise potential bias, and MAPS noted it comes without a new Phase 3Phase 3Larger trials meant to confirm a drug's effects and safety, usually needed before a regulator will consider approving it.Open the glossary study. MAPS, which funded the clinical research completed in 2022 and says it has no active role in Resilient's drug development, also pointed to the FDA's final July 2026 guidance, Psychedelic Drugs: Considerations for Clinical Investigations, as reflecting approaches it developed with the agency.
Key facts
- Kind of item
- Analysis and opinion
- Compound
- MDMA
- Condition
- PTSD
- Organisation
- MAPS
- Regulator
- FDA (United States)
- Jurisdiction
- United States
- Trial phase
- Phase 3
- Source
- MAPS (maps.org)
- Published
- Original
- Read it at maps.org
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: MAPS · maps.org
Connected to
- Kind of item
- Analysis and opinion
- Compound
- MDMA
- Condition
- PTSD
- Organisation
- MAPS
- Regulator
- FDA (United States)
- Jurisdiction
- United States